Taisho Pharmaceutical Holdings Co., Ltd.

Biolinq intends to use the funding to complete the US clinical trial of its unique intradermal glucose biosensor patch, which uses an array of tiny electrochemical sensors to measure glucose levels from the intradermal space just beneath the skin Biolinq glucose sensor. (Credit: Business Wire) US-based medical device company Biolinq has received $58m in a financing round led by Alpha Wave Ventures, to advance the development of its wearable glucose biosensor technology. The funding round has seen participation from Niterra’s corporate venture capital fund jointly operated with Pegasus Tech Ventures, along with existing investors. Existing investors include RiverVest Venture Partners, AXA IM Alts, Global Health Investment, Aphelion Capital, Senvest Management, Features Capital, and Taisho Pharmaceutical. Biolinq intends to use the funding to complete its US clinical trial that evaluates the company’s unique intradermal glucose sensor patch, and its subsequent FDA submission. Biolinq CEO Rich Yang said: “Our technology approach enables access to a coveted, metabolically active compartment of the skin for biosensing without the use of introducer needles or bleeding. “Over the past decade, our team has been pioneering a new biosensor platform designed to inform and inspire, with a mission to reach more people that are in need of simple solutions to improve metabolic health.” Biolinq’s wearable patch, placed on the upper forearm, uses an array of tiny electrochemical sensors to measure glucose levels from the intradermal space just beneath the skin. The wearable patch incorporates an intuitive display that informs users when glucose levels are within a target range and when glucose levels are elevated beyond a healthy range. It combines glucose information with measurements of relative levels of activity in a single device, and enables multi-analyte capabilities, said the medical device maker. Biolinq chairman Dan Bradbury said: “Biolinq’s technology enables a new era for self-monitoring, with a product platform designed to make continuous sensing simple and more accessible. Alpha Wave Global chairman Rick Gerson said: “Companies that disrupt entire industries often don’t originate from a single discipline. “Biolinq has attracted leading experts in biosensor development, consumer electronics design, proprietary materials science, software engineering and semiconductor manufacturing to build a new category of bio-wearables.” In November 2021, Biolinq secured $100m in a Series B financing round to support the development of its micro-array of biosensors designed for continuous glucose monitoring.

California-based Biolinq, a health technology company developing precision multi-analyte wearable biosensors for metabolic health, announced it scored $58 million in financing. Alpha Wave Ventures led the round, with participation from Niterra’s corporate venture capital fund, which is jointly operated with Pegasus Tech Ventures. Existing investors, including AXA IM Alts, Senvest Management, Features Capital, Aphelion Capital, RiverVest Venture Partners, and Taisho Pharmaceutical, also participated in the raise. Biolinq created a wearable patch that evaluates glucose levels and levels of activity. Using small electrochemical sensors, the patch measures glucose levels from the intradermal space beneath the surface of one's skin. The company will use the funds to perform a clinical trial on its glucose sensor and for FDA submission. "Our technology approach enables access to a coveted, metabolically active compartment of the skin for biosensing without the use of introducer needles or bleeding," Rich Yang, CEO of Biolinq, said in a statement. "Over the past decade, our team has been pioneering a new biosensor platform designed to inform and inspire, with a mission to reach more people that are in need of simple solutions to improve metabolic health." EarliTech Diagnostics, a company creating diagnostic and therapeutic offerings for children with autism, secured $21.5 million in Series B funding led by Nexus NeuroTech Ventures and Venture Investors Health Fund. The Georgia-based company offers the EarliPoint Evaluation, a platform to help clinicians diagnose and assess children aged 16-to-30 months with autism. Kids watch a video on a tablet of social interactions. At the same time, a biomarker tracks the child's focus, proxies clinician diagnosis, and assesses the level of function on characteristics such as verbal ability and non-verbal learning. The company will use the funds to advance its technology, further commercialize its product, and advance clinical research. Manifold, an AI-enabled clinical research platform, announced its launch with $15 million in Series A funding led by TQ Ventures. New investors SK Ventures and Calibrate Ventures participated in the round alongside Dr. Sachin H. Jain and existing investors TTCER Partners. The company offers an AI-powered platform for clinical research aimed at streamlining workflows and data management. It allows researchers to manage cohort studies and patient registries, administer observational study workflows and provide a patient portal with surveys, consent tracking and digital outreach. Employee benefits platform Beanstalk Benefits, built out of Redesign Health, announced its launch with $7.5 million in funding. The company provides employees with a platform that allows them to choose their everyday benefits, including health, well-being, and wealth services, instead of having their employer choose for them. The benefits include offerings for chronic condition management, parenting, personal finance, elder care, fertility and mental health services. Employers contract with Beanstalk to provide the varied benefits, not each individual company. "We’ve spent the last year investing in the platform itself. It was important to us to create an intuitive user experience since employees have never picked their own non-insurance benefits before and aren’t necessarily familiar with what’s out there. We think they’re going to be very excited to discover just how tailored they can make their portfolios with all of the benefits innovation that’s out there to meet their unique needs," Matthew Sydney, Beanstalk Benefits CEO and cofounder, told MobiHealthNews in an email. "In terms of next steps, now that the platform is available to the broader market, we’ll be focused on onboarding employers and building out our customer service team. Employers can launch Beanstalk within days of signing on at any time of year, so we’ll be investing to further enhance just how easy it is to work with Beanstalk. We’ll also be continually vetting and adding new benefits solutions to our suite as we aim to create the most comprehensive resource possible under that one employer contract."

Biosensor platform leverages silicon semiconductor manufacturing for scale. Technology designed to provide a better view of metabolic health by combining glucose information with context around activities of daily living in one device. $58 million in funding led by Alpha Wave Ventures. SAN DIEGO--(BUSINESS WIRE)-- Biolinq Incorporated, a healthcare technology company pioneering precision multi-analyte biosensors to improve metabolic health, today announced the completion of $58 million in financing led by Alpha Wave Ventures, with participation from Niterra’s corporate venture capital fund jointly operated with Pegasus Tech Ventures and existing investors RiverVest Venture Partners, AXA IM Alts, Global Health Investment Corporation, Aphelion Capital, Senvest Management, Features Capital and Taisho Pharmaceutical. J.P. Morgan served as placement agent to Biolinq in connection with the financing. This press release features multimedia. View the full release here: Biolinq sensors on a silicon wafer (Photo: Business Wire) The financing will support completion of a U.S. pivotal clinical trial this year, evaluating Biolinq’s proprietary intradermal glucose sensor, and subsequent FDA submission. Designed for simplicity, Biolinq’s wearable patch uses an array of tiny electrochemical sensors to measure glucose levels from the intradermal space just beneath the surface of the skin, combining glucose information with relative levels of activity in one device. “Our technology approach enables access to a coveted, metabolically active compartment of the skin for biosensing without the use of introducer needles or bleeding,” said Rich Yang, CEO, Biolinq. “Over the past decade, our team has been pioneering a new biosensor platform designed to inform and inspire, with a mission to reach more people that are in need of simple solutions to improve metabolic health.” Biolinq's wearable patch, placed on the upper forearm with a clear line of sight, incorporates an intuitive display on the device that informs users when glucose levels are within a target range and when glucose levels are elevated beyond a healthy range. Biolinq's array of sensors on a silicon chip are designed for redundancy, reliability and multi-analyte capabilities. “Companies that disrupt entire industries often don’t originate from a single discipline,” said Rick Gerson, Chairman of Alpha Wave Global. “Biolinq has attracted leading experts in biosensor development, consumer electronics design, proprietary materials science, software engineering and semiconductor manufacturing to build a new category of biowearables. Biolinq is well-positioned to enter the market with a differentiated solution for people living with diabetes.” “Biolinq's technology enables a new era for self-monitoring, with a product platform designed to make continuous sensing simple and more accessible,” said Dan Bradbury, Chairman, Biolinq. “We have a meaningful opportunity to transform care delivery and enable healthier living by opening up a new frontier in continuous sensing.” Biolinq’s intradermal glucose sensor is an investigational device that is not yet cleared or approved by the FDA or any other regulatory authority. About Biolinq Biolinq is a healthcare technology company pioneering precision multi-analyte wearable sensors to improve metabolic health. The company’s biosensor platform is designed to inform and inspire with unparalleled simplicity to support healthier living. With microsensors that reside just below the skin's surface, Biolinq is redefining the future of continuous small molecule biosensing. The company is headquartered in San Diego, CA. For more information, please visit . About Alpha Wave Alpha Wave is a global investment company with three main verticals: private equity, private credit, and public markets. It is led by Rick Gerson, Navroz Udwadia, and Ryan Khoury. Its flagship global private equity fund, Alpha Wave Ventures, aims to invest in best-in-class growth-stage companies and endeavors to be helpful long-term partners to the founders and management teams. Alpha Wave has offices in New York, Miami, London, Monaco, Madrid, Abu Dhabi, Tel Aviv, Bangalore, and Sydney. For more information, please visit . View source version on businesswire.com: Contacts Media Kimberly Ha KKH Advisors 917-291-5744 kimberly.ha@kkhadvisors.com Source: Biolinq Incorporated Smart Multimedia Gallery Photo Biolinq sensors on a silicon wafer (Photo: Business Wire) Photo Biolinq glucose sensor (Photo: Business Wire) Logo View this news release and multimedia online at: